First Tracks Biotherapeutics (TRAX) Financial Statements & Analysis

First Tracks Biotherapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

First Tracks Biotherapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023
Period ending	Dec 2025	Dec 2024	Dec 2023
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	139.61	152.35	0.00
Gross Profit	-139.61	-152.35	0.00
Operating Expenses
Research & Development	139.61	152.35	97.59
Selling, General & Administrative	39.39	28.76	20.87
Operating Expenses	39.39	28.76	118.46
Operating Income	-179.01	-181.10	-118.46
Other Income/Expense
Interest Income	12.94	17.38	12.31
Interest Expense	0.00	0.00	0.00
Other Income/Expense	-0.02	17.40	0.00
Income
Income Before Tax	-166.09	-163.71	-106.15
Income Tax Expense	0.00	0.00	0.00
Net Income	-166.09	-163.71	-106.15
Net Income - Continuous Operations	-166.09	-163.71	-106.15
Net Income - Discontinued Operations	-	-	-
EBITDA	-178.45	-178.70	-116.09
EBIT	-179.01	-181.10	-118.46
Depreciation & Amortization	0.56	2.40	2.38
Earnings Per Share
Basic EPS	-	-	-3.00
Diluted EPS	-	-	-3.00
Basic Shares Outstanding	34.75	34.75	34.75
Diluted Shares Outstanding	34.75	34.75	34.75

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About First Tracks Biotherapeutics Financial Statements

Is First Tracks Biotherapeutics profitable?

No. First Tracks Biotherapeutics reported a net loss of $166.09M in fiscal 2025. In fiscal 2024 it lost $163.71M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition